IL85220A - Precursor protein of apc polypeptide and dna coding therefor - Google Patents

Precursor protein of apc polypeptide and dna coding therefor

Info

Publication number
IL85220A
IL85220A IL85220A IL8522088A IL85220A IL 85220 A IL85220 A IL 85220A IL 85220 A IL85220 A IL 85220A IL 8522088 A IL8522088 A IL 8522088A IL 85220 A IL85220 A IL 85220A
Authority
IL
Israel
Prior art keywords
precursor protein
dna coding
coding therefor
apc polypeptide
fragments
Prior art date
Application number
IL85220A
Other languages
English (en)
Other versions
IL85220A0 (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL85220A0 publication Critical patent/IL85220A0/xx
Publication of IL85220A publication Critical patent/IL85220A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL85220A 1987-01-30 1988-01-27 Precursor protein of apc polypeptide and dna coding therefor IL85220A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873702789 DE3702789A1 (de) 1987-01-30 1987-01-30 Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins

Publications (2)

Publication Number Publication Date
IL85220A0 IL85220A0 (en) 1988-07-31
IL85220A true IL85220A (en) 1993-07-08

Family

ID=6319874

Family Applications (1)

Application Number Title Priority Date Filing Date
IL85220A IL85220A (en) 1987-01-30 1988-01-27 Precursor protein of apc polypeptide and dna coding therefor

Country Status (16)

Country Link
US (1) US5218100A (zh)
EP (1) EP0276723B1 (zh)
JP (2) JP2783407B2 (zh)
KR (1) KR960011524B1 (zh)
CN (1) CN1034576C (zh)
AT (1) ATE98260T1 (zh)
AU (1) AU603179B2 (zh)
CA (1) CA1341033C (zh)
DE (2) DE3702789A1 (zh)
DK (1) DK47588A (zh)
ES (1) ES2061527T3 (zh)
HU (1) HUT46356A (zh)
IL (1) IL85220A (zh)
NZ (1) NZ223312A (zh)
PH (1) PH25795A (zh)
ZA (1) ZA88634B (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
US5015570A (en) * 1988-05-13 1991-05-14 Molecular Therapeutics, Inc. Molecular diagnosis of Alzheimer Disease
JPH03239595A (ja) * 1990-02-16 1991-10-25 Dainippon Printing Co Ltd カード製造方法
AU652997B2 (en) 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
US5455169A (en) * 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5863902A (en) * 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
JP2001521759A (ja) 1997-11-12 2001-11-13 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド ヒトアミロイド前駆体タンパク質遺伝子の翻訳エンハンサーエレメント
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
WO2000002911A2 (en) * 1998-07-10 2000-01-20 Curagen Corporation INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON)
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7196163B2 (en) * 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
KR100900541B1 (ko) 2002-11-14 2009-06-02 삼성전자주식회사 액정 표시 장치용 박막 트랜지스터 기판
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
EP2808032B1 (en) * 2005-12-12 2018-08-01 AC Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
MX2009000476A (es) * 2006-07-14 2009-01-28 Ac Immune Sa Anticuerpo humanizado contra beta amiloide.
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
AR064501A1 (es) * 2006-12-22 2009-04-08 Genentech Inc Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicos
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
PL2170389T3 (pl) * 2007-06-12 2015-03-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
BRPI0818623A2 (pt) * 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
AU2008311367B2 (en) * 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0909898A2 (pt) * 2008-06-12 2015-12-01 Genentech Inc método para a triagem de compostos que inibem a neurodegeneração
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MX2011005481A (es) 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
JP2013510871A (ja) * 2009-11-12 2013-03-28 ジェネンテック， インコーポレイテッド 樹状突起棘の密度を促す方法
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
EP3697927B1 (en) * 2017-10-19 2022-12-14 Bio-Rad Laboratories, Inc. Digital amplification assays with unconventional and/or inverse changes in photoluminescence

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
ATE169673T1 (de) * 1986-11-17 1998-08-15 Scios Inc Rekombiniertes alzheimer amyloid-protein

Also Published As

Publication number Publication date
US5218100A (en) 1993-06-08
JP2783407B2 (ja) 1998-08-06
CA1341033C (en) 2000-06-20
CN1034576C (zh) 1997-04-16
JPS63222693A (ja) 1988-09-16
DE3886060D1 (de) 1994-01-20
DK47588D0 (da) 1988-01-29
ATE98260T1 (de) 1993-12-15
EP0276723B1 (de) 1993-12-08
IL85220A0 (en) 1988-07-31
PH25795A (en) 1991-11-05
EP0276723A3 (de) 1991-05-15
HUT46356A (en) 1988-10-28
DK47588A (da) 1988-07-31
ES2061527T3 (es) 1994-12-16
CN88100542A (zh) 1988-08-10
JP3513795B2 (ja) 2004-03-31
AU603179B2 (en) 1990-11-08
KR960011524B1 (ko) 1996-08-23
JPH10218899A (ja) 1998-08-18
ZA88634B (en) 1988-08-02
EP0276723A2 (de) 1988-08-03
DE3702789A1 (de) 1988-08-18
NZ223312A (en) 1991-10-25
AU1064188A (en) 1988-08-04
KR880009035A (ko) 1988-09-13

Similar Documents

Publication Publication Date Title
IL85220A0 (en) Precursor protein of apc polypeptide,dna coding therefor and diagnostic use of the dna and of the protein
EP0787802A3 (zh)
ZA889033B (en) Vectors and compounds for direct expression of activated human protein c.
NO880268D0 (no) Fremgangsmaate for fremstilling av anti-koagulerende peptider.
ATE184917T1 (de) Rekombinante methode und wirt zur herstellung von xylitol
IT8522668A0 (it) Procedimento per la preparazione di (2,2)-paraciclofani alogenati e miscele di (2,2)-paraciclofani alogenati ottenuti.
EP0209543A4 (en) FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE.
HU902004D0 (en) New trombolitic preparations
EP0373195A4 (en) COMPOSITION FOR IN-VIVO OR IN-VITRO INCREASE IN MELANINE CONTENT OF THE MELANOCYTES AND THEIR USE IN-VITRO.
IT8419730A0 (it) Procedimento per la trasformazione quantitativa di teicoplanina a2fattore 1 in teicoplanina a2fattore 3.
AU4267685A (en) Tissue protein pp 18
AU564556B2 (en) New p-phenylenediamine peptides and reactance containing themfor the determination of proteases of the blood coagulation system
IT8821049A0 (it) Procedimento per l'alchilazione difenoli.
EP0315081A3 (en) Anti-coagulating protein pp4-x, its preparation and use
NO881942D0 (no) Fremgangsmaate for fremstilling av fremmede proteiner i streptomyceten.
GR3005231T3 (zh)
PT79853A (en) Process for the preparation of an highly solubilized protein
NZ224869A (en) Recombinant plasmids coding for the htv coat protein (gag encoded proteins) and vaccines containing these proteins
PT86162A (en) Recombinant protein expression
AU628903B2 (en) Cdna coding for placenta protein 11 (pp11), the isolation and use thereof
AU5110390A (en) Cdna coding for placental protein 9 (pp9), the isolation and use thereof
EP0331743A4 (en) PROTEIN DERIVED FROM A LIVING BODY.
AU7506887A (en) Medical or veterinary instrument
IE873083L (en) Tecombinant alzheimer's amyloid protein.
IE894176L (en) cDNA CODING FOR PLACENTA PROTEIN 11

Legal Events

Date Code Title Description
KB Patent renewed
RH Patent void
MM9K Patent not in force due to non-payment of renewal fees